Cart
sales@molnova.com
ZLDI-8
CAS No. 667880-38-8
ZLDI-8 ( —— )
Catalog No. M22943 CAS No. 667880-38-8
ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 151 | In Stock |
|
| 5MG | 260 | In Stock |
|
| 10MG | 410 | In Stock |
|
| 25MG | 678 | In Stock |
|
| 50MG | 954 | In Stock |
|
| 100MG | 1287 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZLDI-8
-
NoteResearch use only, not for human use.
-
Brief DescriptionZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?
-
DescriptionZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?ZLDI-8 treatment enhanced the susceptibility of HCC cells to a small molecular kinase inhibitor Sorafenib, and chemotherapy agents Etoposide and Paclitaxel.?ZLDI-8 treatment enhanced the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model.?In nude HCC-bearing mice model, ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADAM-17
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number667880-38-8
-
Formula Weight433.52
-
Molecular FormulaC24H23N3O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO:62.5 mg/mL (144.17 mM; Need ultrasonic)
-
SMILESO=C(/C(C(N1)=O)=C/C2=C(C)N(CCOC3=CC=C(C)C=C3C)C4=C2C=CC=C4)NC1=S
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743.
molnova catalog
related products
-
FOY 251
FOY 251 is a proteinase inhibitor, and is an anti-proteolytic active metabolite camostate.FOY-251, an active metabolite of camostat mesilate, on sodium transport in the mouse cortical collecting duct cell line (M-1 cells) and on blood pressure in Dahl salt-sensitive rats.?
-
3,7-Di-O-methylquerc...
3,7-Di-O-methylquercetin shows α-glucosidase inhibition.
-
DL-Tartaric acid
DL-Tartaric acid is a natural product.
